A new study published in the Journal of European Academy of Dermatology and Venerology showed that compared to patients on ...

Apogee's strong financial position, with $731.1 million in cash, funds operations through Q1 2028, de-risking its ambitious ...

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

Raj Chovatiya, MD, PhD, MSCI, highlights the long-term effectiveness of lebrikizumab across diverse patients, including those with prior biologic use, positioning it as a potential first-line ...

Medically reviewed by Casey Gallagher, MD Atopic dermatitis (the most common type of eczema) causes dry, itchy skin with ...

The atopic dermatitis (AD) treatment landscape is witnessing intensified competition with several novel therapies nearing market entry. While biologics like dupilumab have already transformed care, ...

Series C round led by Deep Track Capital with participation from additional new and existing investorsFinancing will fund early-to-mid-stage ...

A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.

Atopic Dermatitis AD and Contact Dermatitis CD are skin conditions that lead to skin inflammation however their causes and ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

With the recent developments in the atopic dermatitis (AD) market, the field is becoming more competitive as novel therapies are soon anticipated to enter the market. This evolution may benefit AD ...